ArchiMed, the Lyon and New York based healthcare investment firm, has laid out how it intends to deploy its 1.75 billion euro fund, with chairman Denis Ribon telling PE Hub that artificial intelligence is changing the firm’s deal selection and its plans for portfolio companies. The same report covered the firm’s majority acquisition of Genetica, a Brazilian wastewater and environmental services specialist, an example of the healthcare adjacent infrastructure the fund targets.
ArchiMed occupies the mid market healthcare niche that generalist sponsors have retreated from as rates rose: medtech, diagnostics, pharma services and environmental health, bought platform by platform across Europe and the Americas. A 1.75 billion euro vehicle makes it one of the largest dedicated pools competing for those assets.
The AI claim deserves its sceptical reading, since every fund deck now carries one, but in healthcare operations the use cases, imaging, documentation, diagnostics triage, are nearer to revenue than most. This item is single sourced to the firm’s own interview and is graded C on that basis.